Organon Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Kevin Ali
Chief executive officer
US$14.8m
Total compensation
| CEO salary percentage | 8.4% |
| CEO tenure | 3yrs |
| CEO ownership | 0.05% |
| Management average tenure | 3yrs |
| Board average tenure | 3yrs |
Recent management updates
Recent updates
Organon & Co.'s (NYSE:OGN) CEO Might Not Expect Shareholders To Be So Generous This Year
May 29
Organon's (NYSE:OGN) Solid Profits Have Weak Fundamentals
May 10Four Reasons Why Organon Stock Is A Good Buy
May 07Little Excitement Around Organon & Co.'s (NYSE:OGN) Earnings
Apr 21Organon Stock Is Still Worth A Look
Feb 24Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28
Feb 19Organon Q4 And Full Year 2023 Earnings Review - Positive Updates At Last
Feb 16Organon: What I'm Looking For In This 8% Yield In 2024
Jan 03High Risk, High Reward: Why 8.5%-Yielding Organon Could Be Up To 90% Undervalued
Dec 19Organon: It's Darkest Before The Dawn
Nov 30Organon: Poor Q3 Earnings Make Bear Case, But Dividend Is Saving Grace
Nov 07Organon (NYSE:OGN) Has Affirmed Its Dividend Of $0.28
Nov 05Organon: The Federal Reserve Black Swan (Rating Upgrade)
Oct 046% Yield And Significantly Undervalued: A Closer Look At Organon
Sep 10Organon Q2 2023 Earnings Review: Incremental Growth With A Slather Of Risk
Aug 10Organon & Co.: A Tough Spot To Be In Right Now
Jul 16Organon goes ex-dividend tomorrow
Feb 23Organon & Co. (NYSE:OGN) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?
Feb 19Is There Anything Organic Or Interesting About Organon?
Feb 07Organon goes ex-dividend tomorrow
Nov 09Organon's (NYSE:OGN) Dividend Will Be $0.28
Nov 08Take Care Before Diving Into The Deep End On Organon & Co. (NYSE:OGN)
Nov 05Organon: Thoughts Ahead Of Q3 Earnings
Oct 31Organon: What Is The Recipe?
Aug 31Oragenics announces early toxicology data for intranasal COVID-19 vaccine
Aug 24Organon, Samsung Bioepis Humira biosimilar Hadlima high concentration dosage gets FDA nod
Aug 17Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28
Aug 07Organon Q2 2022 Earnings Preview
Aug 03Organon in pact with Cirqle Biomedical for contraceptive candidate
Jul 28Organon: Some Uncomfortable Questions Ahead Of Q2 Earnings
Jul 18Organon Vs. Viatris: Who Is The Clear Winner?
Jun 20Organon: Maximum Optimism
Apr 28CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | US$1b |
| Dec 31 2023 | US$15m | US$1m | US$1b |
| Sep 30 2023 | n/a | n/a | US$585m |
| Jun 30 2023 | n/a | n/a | US$754m |
| Mar 31 2023 | n/a | n/a | US$746m |
| Dec 31 2022 | US$14m | US$1m | US$917m |
| Sep 30 2022 | n/a | n/a | US$1b |
| Jun 30 2022 | n/a | n/a | US$1b |
| Mar 31 2022 | n/a | n/a | US$1b |
| Dec 31 2021 | US$19m | US$1m | US$1b |
Compensation vs Market: Kevin's total compensation ($USD14.83M) is above average for companies of similar size in the US market ($USD8.45M).
Compensation vs Earnings: Kevin's compensation has been consistent with company performance over the past year.
CEO
Kevin Ali (64 yo)
3yrs
Tenure
US$14,832,272
Compensation
Mr. Kevin Ali is Chief Executive Officer and Director of Organon & Co. since June 2, 2021. Mr. Ali served as the President of Global Enterprise Portfolio Strategy at Merck & Co., Inc. from 2019 to 2021 and...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3yrs | US$14.83m | 0.053% $ 2.9m | |
| Executive VP & CFO | 3yrs | US$5.21m | 0.034% $ 1.9m | |
| Executive VP | 1.4yrs | US$3.19m | 0.011% $ 615.9k | |
| Executive VP & Chief Commercial Officer | 3.4yrs | US$3.84m | 0.020% $ 1.1m | |
| Executive VP and Head of Manufacturing & Supply | 3yrs | US$3.74m | 0.016% $ 862.5k | |
| Executive VP & Chief Information Officer | 3yrs | no data | 0.019% $ 1.0m | |
| Head of Investor Relations | 3.4yrs | no data | no data | |
| Chief Ethics & Compliance Officer | no data | no data | no data | |
| Chief Communications Officer | no data | no data | no data | |
| Chief Business Development Officer | no data | no data | no data | |
| Executive VP & Chief Human Resources Officer | 3yrs | no data | 0.012% $ 642.5k | |
| Executive VP & Head of Global Business Services | 3yrs | no data | 0.0087% $ 472.5k |
3.0yrs
Average Tenure
56yo
Average Age
Experienced Management: OGN's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3yrs | US$14.83m | 0.053% $ 2.9m | |
| Independent Chairman of the Board | 3yrs | US$450.00k | no data | |
| Independent Director | 3yrs | US$335.00k | no data | |
| Independent Director | 3yrs | US$320.00k | 0.00025% $ 13.6k | |
| Independent Director | 3yrs | US$320.00k | no data | |
| Independent Director | 3yrs | US$330.00k | no data | |
| Independent Director | 3yrs | US$320.00k | no data | |
| Independent Director | 3yrs | US$345.00k | 0% $ 0 | |
| Independent Director | 3yrs | US$320.00k | no data | |
| Independent Director | 3yrs | US$330.00k | no data | |
| Independent Director | 3yrs | US$320.00k | 0% $ 0 | |
| Independent Director | 3yrs | US$330.00k | 0% $ 0 |
3.0yrs
Average Tenure
64yo
Average Age
Experienced Board: OGN's board of directors are considered experienced (3 years average tenure).